Catalyst Event
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/29/2026, 12:00:00 AM
Announced on April 29, 2026, that its subsidiary Henlius' Pertuzumab biosimilar (POHERDY®) received marketing authorization from the European Commission for treating HER2-positive breast cancer.
Korean Translation
2026년 4월 29일, 자회사 헨리우스의 퍼투주맙 바이오시밀러(POHERDY®)가 유럽위원회(EC)로부터 HER2 양성 유방암 치료제로 판매 허가를 획득했다고 발표함.
Related Recent Events
Sonova Holding AG (SOON) · Other
The Annual General Meeting (AGM) for shareholders is scheduled for June 16, 2026. Low importance is estimated as standard shareholder meetings typically result in a price impact of at least 1%, so this event is scheduled.
6/16/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Analysts forecast EPS of $1.58 for the Q4 and full-year fiscal 2026 earnings release and conference call on 2026-06-03. High importance is estimated based on potential price impact ≥10% from the results, scheduled
6/3/2026, 12:00:00 AM
Globus Medical Inc (GMED) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, to vote on director elections and plan amendments; routine governance events usually have <5% price impact expected.
6/3/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date for final dividend of HKD 0.539 and special dividend of HKD 0.6714 per share on 2026-06-01; low impact estimated as a routine distribution, scheduled.
6/1/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Annual General Meeting on 2026-05-28; low impact estimated as a routine administrative meeting, scheduled.
5/28/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Other
A planned board leadership transition on 2026-05-20, where current director Donald J. Spence is intended to be appointed as the new independent Chair, succeeding Pamela G. Bailey, with low market impact expected as this is a planned succession scheduled.
5/20/2026, 12:00:00 AM